Nat Rev Clin Oncol:癌症相关加速衰老和生物行为调节剂:研究和临床治疗的框架

2021-12-27 MedSci原创 MedSci原创

越来越多的证据表明,接受细胞毒性治疗(如化疗或放疗)的癌症患者身体和认知衰老加速的风险增加。此外,加速的生物老化被怀疑是许多观察到的影响背后的驱动力。在这篇综述中,我们描述了生物衰老的机制以及它们如何

越来越多的证据表明,接受细胞毒性治疗(如化疗或放疗)的癌症患者身体和认知衰老加速的风险增加。此外,加速的生物老化被怀疑是许多观察到的影响背后的驱动力。在这篇综述中,我们描述了生物衰老的机制以及它们如何应用于癌症患者。我们强调特定行为因素的重要作用,即压力、睡眠和与生活方式相关的因素,如身体活动、体重管理、饮食和药物使用,在癌症患者和癌症幸存者加速衰老中发挥重要作用。我们还提出了一个框架,说明可改变的行为如何操作,以增加加速衰老的风险,提供保护,或在生物水平和患者报告的结果方面促进恢复力。

要点:

癌症及其治疗被认为会加速生物衰老,导致癌症幸存者出现不良的认知、行为和功能结果。

已知可改变的宿主特异性因素会影响非癌症个体的衰老生物学,包括社会心理压力、睡眠不足、缺乏身体活动、肥胖以及烟草和酒精的使用。

针对这些宿主因素的行为干预和/或修改可能会直接改变癌症患者和癌症幸存者的生物衰老过程,从而改善健康和寿命。

我们建议在与癌症相关的年龄加速模型中考虑这些宿主因素,并将旨在减轻压力、改善睡眠健康、增加身体活动、控制体重和/或减少酒精和烟草使用的干预措施作为解决问题的有希望的方法进行研究。 在这种情况下加速老化。

总之,本评论概述了越来越多的将癌症及其治疗与加速的身体、认知和生物衰老联系起来的文献,并将该模型扩展到包括可能改善这些衰老模式的几个重要行为调节剂。已知影响非癌症个体衰老生物学的关键行为包括感知压力、睡眠障碍和失眠、久坐不动的生活方式、肥胖、不良饮食和物质使用。在此,我们提出这些因素也可能在癌症背景下充当调节剂并导致加速老化。通过直接改变生物衰老模式,干预以减轻压力、改善睡眠健康、增加体育锻炼、控制体重和/或减少酒精和烟草的使用都可能对患者和幸存者的长期健康和寿命有益。我们为未来的研究提出了几个方向,旨在仔细确定干预措施的可行目标。

 

评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1953191, encodeId=946c195319137, content=<a href='/topic/show?id=d441e1440e8' target=_blank style='color:#2F92EE;'>#癌症相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71440, encryptionId=d441e1440e8, topicName=癌症相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Oct 07 00:24:33 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885574, encodeId=6f7418855e408, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Jul 28 11:24:33 CST 2022, time=2022-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866428, encodeId=44e81866428e9, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Jun 21 06:24:33 CST 2022, time=2022-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525841, encodeId=a42f1525841d6, content=<a href='/topic/show?id=c93e228e889' target=_blank style='color:#2F92EE;'>#临床治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22878, encryptionId=c93e228e889, topicName=临床治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a68911667380, createdName=xuyong527, createdTime=Wed Dec 29 04:24:33 CST 2021, time=2021-12-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1953191, encodeId=946c195319137, content=<a href='/topic/show?id=d441e1440e8' target=_blank style='color:#2F92EE;'>#癌症相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71440, encryptionId=d441e1440e8, topicName=癌症相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Oct 07 00:24:33 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885574, encodeId=6f7418855e408, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Jul 28 11:24:33 CST 2022, time=2022-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866428, encodeId=44e81866428e9, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Jun 21 06:24:33 CST 2022, time=2022-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525841, encodeId=a42f1525841d6, content=<a href='/topic/show?id=c93e228e889' target=_blank style='color:#2F92EE;'>#临床治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22878, encryptionId=c93e228e889, topicName=临床治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a68911667380, createdName=xuyong527, createdTime=Wed Dec 29 04:24:33 CST 2021, time=2021-12-29, status=1, ipAttribution=)]
    2022-07-28 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=1953191, encodeId=946c195319137, content=<a href='/topic/show?id=d441e1440e8' target=_blank style='color:#2F92EE;'>#癌症相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71440, encryptionId=d441e1440e8, topicName=癌症相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Oct 07 00:24:33 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885574, encodeId=6f7418855e408, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Jul 28 11:24:33 CST 2022, time=2022-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866428, encodeId=44e81866428e9, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Jun 21 06:24:33 CST 2022, time=2022-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525841, encodeId=a42f1525841d6, content=<a href='/topic/show?id=c93e228e889' target=_blank style='color:#2F92EE;'>#临床治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22878, encryptionId=c93e228e889, topicName=临床治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a68911667380, createdName=xuyong527, createdTime=Wed Dec 29 04:24:33 CST 2021, time=2021-12-29, status=1, ipAttribution=)]
    2022-06-21 minlingfeng
  4. [GetPortalCommentsPageByObjectIdResponse(id=1953191, encodeId=946c195319137, content=<a href='/topic/show?id=d441e1440e8' target=_blank style='color:#2F92EE;'>#癌症相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71440, encryptionId=d441e1440e8, topicName=癌症相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Oct 07 00:24:33 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885574, encodeId=6f7418855e408, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Jul 28 11:24:33 CST 2022, time=2022-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866428, encodeId=44e81866428e9, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Jun 21 06:24:33 CST 2022, time=2022-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525841, encodeId=a42f1525841d6, content=<a href='/topic/show?id=c93e228e889' target=_blank style='color:#2F92EE;'>#临床治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22878, encryptionId=c93e228e889, topicName=临床治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a68911667380, createdName=xuyong527, createdTime=Wed Dec 29 04:24:33 CST 2021, time=2021-12-29, status=1, ipAttribution=)]